Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
May 31, 2007
Primary Completion Date
August 31, 2007
Study Completion Date
August 31, 2007
Conditions
Chronic Fatigue Syndrome
Interventions
DRUG
valganciclovir
Trial Locations (1)
94305
Stanford University Medical Center, Stanford
All Listed Sponsors
lead
Stanford University
OTHER
NCT00478465 - Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) | Biotech Hunter | Biotech Hunter